Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THYTECH2: thyTreg in COVID-19 and ARDS
NCT06052436Phase 2Recruiting
- Sponsor
- Gregorio Marañón University General Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2027
- Modality
- Regulatory T Cells (Tregs), Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic thyTreg in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), sponsored by Gregorio Marañón University General Hospital. Started Jun 2023; status: recruiting.
02
Drugs
allogeneic thyTreg
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT06052436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052436.